Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System

• প্রধান লেখক: Giuseppe Cicala (লেখক), Giulia Russo (লেখক), Vincenza Santoro (লেখক), Tindara Franchina (লেখক), Nicola Silvestris (লেখক), Mariacarmela Santarpia (লেখক), Edoardo Spina (লেখক), Maria Antonietta Barbieri (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: MDPI AG, 2024-09-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

<b>Background/Objectives</b>: Monoclonal antibodies (mAbs) have revolutionized multiple myeloma (MM) treatment. However, post-marketing data on their neuropsychiatric safety are limited. This study aimed to evaluate neuropsychiatric adverse events (AEs) related to mAbs used for MM throug...